{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T11:31:50Z","timestamp":1785411110125,"version":"3.56.0"},"reference-count":11,"publisher":"American Association for Cancer Research (AACR)","issue":"3","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5,5]]},"abstract":"<jats:title>Summary:<\/jats:title>\n                  <jats:p>Drekolias and colleagues report a therapy-specific prognostic model integrating mutational and cytogenetic features to risk-stratify survival in patients with acute myeloid leukemia treated with venetoclax-based regimens, providing a clinically relevant framework amid a rapidly expanding landscape of competing models.<\/jats:p>\n                  <jats:p>See related article by Drekolias et al., p. 403<\/jats:p>","DOI":"10.1158\/2643-3230.bcd-26-0055","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T13:34:31Z","timestamp":1774964071000},"page":"339-342","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Models, Models, Everywhere: But Which One Should Guide Care?"],"prefix":"10.1158","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8506-0624","authenticated-orcid":false,"given":"Curtis A.","family":"Lachowiez","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/009avj582","id-type":"ROR","asserted-by":"publisher"}],"name":"Oregon Health & Science University 1 Department of Hematology and Medical Oncology, Knight Cancer Institute, , Portland, Oregon."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8980-3202","authenticated-orcid":false,"given":"Sanam","family":"Loghavi","sequence":"additional","affiliation":[{"name":"2Department of Hematopathology, MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,3,31]]},"reference":[{"key":"2026050503060780800_bib1","first-page":"403","article-title":"Prognostic model combining mutational and cytogenetic profiles in acute myeloid leukemia treated with venetoclax and hypomethylating agents","volume":"7","author":"Drekolias","year":"2026","journal-title":"Blood Cancer Discov"},{"key":"2026050503060780800_bib2","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"key":"2026050503060780800_bib3","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1182\/blood.2024024944","article-title":"Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine","volume":"144","author":"D\u00f6hner","year":"2024","journal-title":"Blood"},{"key":"2026050503060780800_bib4","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1182\/blood.2024026925","article-title":"Refined ELN 2024 risk stratification improves survival prognostication following venetoclax-based therapy in AML","volume":"144","author":"Lachowiez","year":"2024","journal-title":"Blood"},{"key":"2026050503060780800_bib5","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1002\/ajh.27564","article-title":"Mayo genetic risk models for newly diagnosed acute myeloid leukemia treated with venetoclax+ hypomethylating agent","volume":"100","author":"Gangat","year":"2025","journal-title":"Am J Hematol"},{"key":"2026050503060780800_bib6","doi-asserted-by":"crossref","first-page":"100125","DOI":"10.1016\/j.bneo.2025.100125","article-title":"Beat AML genetic risk stratification model in a cohort of older VEN\/HMA-treated patients with AML","volume":"2","author":"Hoff","year":"2025","journal-title":"Blood Neoplasia"},{"key":"2026050503060780800_bib7","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/s41586-024-08137-x","article-title":"RAS-mutant leukaemia stem cells drive clinical resistance to venetoclax","volume":"636","author":"Sango","year":"2024","journal-title":"Nature"},{"issue":"Supplement 1","key":"2026050503060780800_bib8","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1182\/blood-2025-453","article-title":"Prognostic risk integration for survival modeling (PRISM) in newly diagnosed acute myeloid leukemia treated with venetoclax: a multinational retrospective cohort study","volume":"146","author":"Lachowiez","year":"2025","journal-title":"Blood"},{"key":"2026050503060780800_bib9","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1158\/2643-3230.BCD-24-0256","article-title":"Genetic and phenotypic correlates of clinical outcomes with venetoclax in acute myeloid leukemia: the GEN-PHEN-VEN study","volume":"6","author":"Lachowiez","year":"2025","journal-title":"Blood Cancer Discov"},{"key":"2026050503060780800_bib10","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1182\/blood.2024024968","article-title":"Ex vivo venetoclax sensitivity predicts clinical response in acute myeloid leukemia in the prospective VenEx trial","volume":"145","author":"Kyt\u00f6l\u00e4","year":"2025","journal-title":"Blood"},{"key":"2026050503060780800_bib11","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1158\/2159-8290.CD-22-0939","article-title":"Combinatorial BCL2 family expression in acute myeloid leukemia stem cells predicts clinical response to azacitidine\/venetoclax","volume":"13","author":"Waclawiczek","year":"2023","journal-title":"Cancer Discov"}],"container-title":["Blood Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/doi\/10.1158\/2643-3230.BCD-26-0055\/3756783\/bcd-26-0055.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/7\/3\/339\/3783082\/bcd-26-0055.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/7\/3\/339\/3783082\/bcd-26-0055.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T07:06:14Z","timestamp":1777964774000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article\/7\/3\/339\/784437\/Models-Models-Everywhere-But-Which-One-Should"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,31]]},"references-count":11,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3,31]]},"published-print":{"date-parts":[[2026,5,5]]}},"URL":"https:\/\/doi.org\/10.1158\/2643-3230.bcd-26-0055","relation":{},"ISSN":["2643-3230","2643-3249"],"issn-type":[{"value":"2643-3230","type":"print"},{"value":"2643-3249","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,31]]}}}